The silent chest in acute asthma is the most dangerous auscultatory finding in acute respiratory medicine — it indicates that airflow is so severely reduced that there is insufficient gas movement to generate audible wheeze. This is counterintuitively reassuring to inexperienced clinicians who may interpret absence of wheeze as improvement. The mechanism: in extremis, the patient cannot generate sufficient inspiratory flow to vibrate bronchial walls (which produce wheeze). The chest is silent because the patient is about to arrest — not because they are better. Any acute asthmatic whose wheeze disappears while they are still distressed and not improving is deteriorating rapidly. Associated features of near-fatal asthma: the patient is often sitting bolt-upright, unable to speak more than one word at a time, using all accessory muscles, and visibly exhausted. The normal or rising CO₂ on blood gas (in an asthmatic who should be hyperventilating) confirms imminent respiratory failure — a PaCO₂ of 5 kPa or above in a distressed asthmatic is a pre-arrest CO₂.

PEF measurement is the most important objective assessment tool in acute asthma — it gives an objective, reproducible measure of expiratory airflow limitation that distinguishes severity grades precisely. The BTS/SIGN guideline severity thresholds are percentages of the patient's own best PEF (their personal best, ideally from an asthma review within the last year) or predicted PEF (from standard nomograms using age/height/sex). The key clinical application: a patient with a personal best of 500 L/min who achieves 400 L/min (80%) in the GP surgery is having a moderate exacerbation; the same PEF of 400 L/min in a patient whose personal best is 600 L/min (67%) is acute severe. Percentage of personal best is more clinically meaningful than absolute values. Every patient with asthma should know their personal best PEF — ask at every asthma review and record it. If personal best is unknown, use predicted PEF from standard tables.

The arterial blood gas interpretation in acute asthma follows a counterintuitive logic — in mild to moderate acute asthma, patients hyperventilate from hypoxaemia-driven respiratory drive, producing hypocapnia (low PaCO₂, typically 3.5-4.5 kPa) and a respiratory alkalosis (pH >7.45). This is the expected finding in someone working hard to breathe. As asthma worsens and respiratory muscle fatigue develops, the patient can no longer maintain the hyperventilatory response — CO₂ begins to rise toward 'normal' (5-6 kPa) or above normal (>6 kPa). This normocapnia or hypercapnia in a severely distressed asthmatic patient indicates decompensation and impending respiratory arrest. The diagnostic rule: a PaCO₂ above 4.5 kPa in a patient with clinically severe acute asthma should be treated as a pre-arrest situation requiring immediate senior support, intubation preparation, and ICU transfer.

The written asthma action plan (WAAP) is one of the most effective single interventions in asthma management — multiple systematic reviews demonstrate that a personalised WAAP reduces asthma hospitalisation by approximately 30%, A&E attendances by approximately 25%, and asthma deaths. Despite this evidence, surveys consistently show that fewer than 30% of asthma patients in UK primary care have a written action plan. The RCGP and NICE QS25 asthma standard include provision of a WAAP as a quality indicator. The action plan should be personalised with the patient's own personal best PEF, specific dose instructions for SABA escalation, when to start prednisolone (and at what dose), and exact criteria for calling 999. The BTS/SIGN asthma guideline provides template WAAP formats that can be downloaded and completed at the point of the review — this takes approximately 3 minutes and can be done by a trained asthma nurse.

The decision to call 999 for acute asthma versus managing in primary care is determined by objective severity markers, not by symptoms alone — a GP facing an acutely unwell asthmatic must apply the BTS/SIGN severity classification within the first 60 seconds: measure PEF (as % personal best), count RR, count HR, assess speech, and measure SpO₂. If ANY of the acute severe or life-threatening criteria are met, 999 is called simultaneously with initiating treatment. The treatment must not wait for the ambulance — while awaiting the ambulance: O₂ via non-rebreather mask at 15 L/min, nebulised salbutamol 5 mg driven by O₂ (back-to-back if necessary), prednisolone 40-50 mg PO (or IV hydrocortisone 200 mg if unable to swallow), and if life-threatening: IV or nebulised ipratropium 500 mcg and consideration of IV magnesium sulphate 2g over 20 minutes. The GP practice must have adequate equipment: O₂ cylinder + non-rebreather mask, nebuliser driven by O₂, IV access equipment, and injectable hydrocortisone.

The magnesium sulphate 2g IV infusion for acute severe or life-threatening asthma is a BTS/SIGN Grade A recommendation that remains significantly underused in both primary care and emergency departments — the mechanism: magnesium acts as a calcium channel antagonist, blocking calcium-mediated smooth muscle contraction in bronchial walls, producing bronchodilation. It also inhibits acetylcholine release at the neuromuscular junction (reducing bronchospasm) and has anti-inflammatory effects. Clinical trials (including the 3Mg trial, JAMA 2013) demonstrate that IV magnesium significantly reduces the need for ICU admission and improves PEF in acute severe asthma when added to standard bronchodilators and corticosteroids. The dose is 2g (2000 mg, or 8 mmol) of MgSO₄ given as a slow IV infusion over 20 minutes — given once only (unlike regular nebulisers). GPs with IV access in acute severe asthma should consider administering magnesium sulphate while awaiting ambulance transfer — it is safe, effective, and can be administered outside the hospital setting.

MART therapy (Maintenance And Reliever Therapy) using a budesonide/formoterol inhaler is the most important change in asthma management over the last decade — MART replaces the previous two-inhaler approach (separate maintenance ICS/LABA + SABA reliever) with a single inhaler that serves both purposes. The key pharmacological principle: formoterol is a fast-acting, long-acting beta-2 agonist — its onset of action is as fast as salbutamol (approximately 1-3 minutes) but its duration is 12 hours. This allows formoterol-containing ICS/LABA inhalers (Symbicort, DuoResp, Fobumix) to be used both as regular maintenance therapy AND as a reliever. The clinical benefit: when symptoms increase, the patient takes an extra reliever puff — and each extra puff is also a dose of ICS (budesonide), providing immediate anti-inflammatory treatment at the exact moment of inflammation. MART reduces severe exacerbation rates by approximately 35-40% compared to fixed-dose ICS/LABA + SABA reliever in trials. NICE NG80 (updated 2024) makes MART the preferred approach from step 3 in adults with inadequately controlled asthma.

The flu vaccine in asthma is a mandatory annual quality standard (QOF indicator RES004) and is one of the most evidence-based preventive interventions for any respiratory condition — influenza is the most common identified trigger for severe asthma exacerbations requiring hospitalisation in adults, particularly in the autumn-winter season. Influenza vaccination reduces asthma-related hospital admissions by approximately 30-35% in RCTs and reduces the frequency of severe exacerbations. The recommended vaccine: quadrivalent inactivated influenza vaccine (QIV or adjuvanted QAIV for ≥65s) — annual offer September-November. A proportion of patients with asthma are falsely concerned that the flu vaccine will 'trigger their asthma' — this concern is based on anecdotal experience with early whole-virus influenza vaccines (which could cause mild respiratory symptoms). Modern inactivated influenza vaccines do not trigger asthma exacerbations — GPs should proactively address this misconception at every opportunity.

The SABA over-prescription monitoring principle is one of the most important safety signals in asthma management at a practice population level — the publication of the National Review of Asthma Deaths (NRAD) in 2014 and the GINA-endorsed SABINA programme established that SABA over-prescription is a pharmacoepidemiological red flag for poor asthma control and increased mortality. The thresholds: prescription of more than 3 SABA inhalers (200 doses each) per year indicates poorly controlled asthma requiring review; prescription of 12 or more per year is associated with a significantly elevated risk of severe exacerbation and death. NHS England requires practices to run searches identifying patients prescribed excessive SABA to enable proactive review and treatment optimisation. GPs who are prescribing salbutamol inhalers to asthma patients at repeat intervals of less than 8 weeks (suggesting use of more than one canister per month) must proactively review these patients.